BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 29907864)

  • 1. Bladder cancer recurrence surveillance by urine metabolomics analysis.
    Loras A; Trassierra M; Sanjuan-Herráez D; Martínez-Bisbal MC; Castell JV; Quintás G; Ruiz-Cerdá JL
    Sci Rep; 2018 Jun; 8(1):9172. PubMed ID: 29907864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Follow-up in non-muscle-invasive bladder cancer-International Bladder Cancer Network recommendations.
    Kassouf W; Traboulsi SL; Schmitz-Dräger B; Palou J; Witjes JA; van Rhijn BW; Grossman HB; Kiemeney LA; Goebell PJ; Kamat AM
    Urol Oncol; 2016 Oct; 34(10):460-8. PubMed ID: 27368880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary Metabolic Signatures Detect Recurrences in Non-Muscle Invasive Bladder Cancer.
    Loras A; Martínez-Bisbal MC; Quintás G; Gil S; Martínez-Máñez R; Ruiz-Cerdá JL
    Cancers (Basel); 2019 Jun; 11(7):. PubMed ID: 31261883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic relevance of positive urine markers in patients with negative cystoscopy during surveillance of bladder cancer.
    Todenhöfer T; Hennenlotter J; Guttenberg P; Mohrhardt S; Kuehs U; Esser M; Aufderklamm S; Bier S; Harland N; Rausch S; Gakis G; Stenzl A; Schwentner C
    BMC Cancer; 2015 Mar; 15():155. PubMed ID: 25884545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urinary UBC Rapid and NMP22 Test for Bladder Cancer Surveillance in Comparison to Urinary Cytology: Results from a Prospective Single-Center Study.
    Pichler R; Tulchiner G; Fritz J; Schaefer G; Horninger W; Heidegger I
    Int J Med Sci; 2017; 14(9):811-819. PubMed ID: 28824318
    [No Abstract]   [Full Text] [Related]  

  • 6. Bladder cancer biomarker discovery using global metabolomic profiling of urine.
    Wittmann BM; Stirdivant SM; Mitchell MW; Wulff JE; McDunn JE; Li Z; Dennis-Barrie A; Neri BP; Milburn MV; Lotan Y; Wolfert RL
    PLoS One; 2014; 9(12):e115870. PubMed ID: 25541698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic predictive value of Xpert Bladder Cancer Monitor in the follow-up of patients affected by non-muscle invasive bladder cancer.
    D Elia C; Pycha A; Folchini DM; Mian C; Hanspeter E; Schwienbacher C; Vjaters E; Pycha A; Trenti E
    J Clin Pathol; 2019 Feb; 72(2):140-144. PubMed ID: 30355587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urinary markers in the everyday diagnosis of bladder cancer.
    Dal Moro F; Valotto C; Guttilla A; Zattoni F
    Urologia; 2013; 80(4):265-75. PubMed ID: 24419920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased accuracy of a novel mRNA-based urine test for bladder cancer surveillance.
    Pichler R; Fritz J; Tulchiner G; Klinglmair G; Soleiman A; Horninger W; Klocker H; Heidegger I
    BJU Int; 2018 Jan; 121(1):29-37. PubMed ID: 28941000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer.
    Roperch JP; Grandchamp B; Desgrandchamps F; Mongiat-Artus P; Ravery V; Ouzaid I; Roupret M; Phe V; Ciofu C; Tubach F; Cussenot O; Incitti R
    BMC Cancer; 2016 Sep; 16(1):704. PubMed ID: 27586786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Replacing cystoscopy by urine markers in the follow-up of patients with low-risk non-muscle-invasive bladder cancer?-An International Bladder Cancer Network project.
    Schmitz-Dräger C; Bonberg N; Pesch B; Todenhöfer T; Sahin S; Behrens T; Brüning T; Schmitz-Dräger BJ
    Urol Oncol; 2016 Oct; 34(10):452-9. PubMed ID: 27381893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bladder cancer biomarker screening based on non-targeted urine metabolomics.
    Li J; Cheng B; Xie H; Zhan C; Li S; Bai P
    Int Urol Nephrol; 2022 Jan; 54(1):23-29. PubMed ID: 34850327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stepwise application of urine markers to detect tumor recurrence in patients undergoing surveillance for non-muscle-invasive bladder cancer.
    Todenhöfer T; Hennenlotter J; Esser M; Mohrhardt S; Aufderklamm S; Böttge J; Rausch S; Mischinger J; Bier S; Gakis G; Kuehs U; Stenzl A; Schwentner C
    Dis Markers; 2014; 2014():973406. PubMed ID: 25587206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Decision Making in Surveillance of Non-Muscle-Invasive Bladder Cancer: The Evolving Roles of Urinary Cytology and Molecular Markers.
    Zuiverloon TCM; de Jong FC; Theodorescu D
    Oncology (Williston Park); 2017 Dec; 31(12):855-62. PubMed ID: 29297169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-life Experience: Early Recurrence With Hexvix Photodynamic Diagnosis-assisted Transurethral Resection of Bladder Tumour vs Good-quality White Light TURBT in New Non-muscle-invasive Bladder Cancer.
    Mariappan P; Rai B; El-Mokadem I; Anderson CH; Lee H; Stewart S; Donat R
    Urology; 2015 Aug; 86(2):327-31. PubMed ID: 26142924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct quantitative detection for cell-free miR-155 in urine: a potential role in diagnosis and prognosis for non-muscle invasive bladder cancer.
    Zhang X; Zhang Y; Liu X; Fang A; Wang J; Yang Y; Wang L; Du L; Wang C
    Oncotarget; 2016 Jan; 7(3):3255-66. PubMed ID: 26657502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosis of bladder cancer and prediction of survival by urinary metabolomics.
    Jin X; Yun SJ; Jeong P; Kim IY; Kim WJ; Park S
    Oncotarget; 2014 Mar; 5(6):1635-45. PubMed ID: 24721970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery and validation of potential urinary biomarkers for bladder cancer diagnosis using a pseudotargeted GC-MS metabolomics method.
    Zhou Y; Song R; Ma C; Zhou L; Liu X; Yin P; Zhang Z; Sun Y; Xu C; Lu X; Xu G
    Oncotarget; 2017 Mar; 8(13):20719-20728. PubMed ID: 28157703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Clinical Research Office of the Endourological Society (CROES) Multicentre Randomised Trial of Narrow Band Imaging-Assisted Transurethral Resection of Bladder Tumour (TURBT) Versus Conventional White Light Imaging-Assisted TURBT in Primary Non-Muscle-invasive Bladder Cancer Patients: Trial Protocol and 1-year Results.
    Naito S; Algaba F; Babjuk M; Bryan RT; Sun YH; Valiquette L; de la Rosette J;
    Eur Urol; 2016 Sep; 70(3):506-15. PubMed ID: 27117749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
    Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M
    Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.